Gerard A. Silvestri, CHEST 2022: Managing Complications in the Treatment of Lung Cancer (Part 2)

Varenicline was approved as a replacement therapy for smoking back in 2007 in Australia, the uptake for varenicline has remained high despite issues associated with patient adherence and access to the therapy. In this interview, touchRESPIRATORY were delighted to speak with Prof. Michael Abramson (Monash University, Victoria, Australia) to discuss his randomized, placebo-controlled trial evaluating […]

The SEISMIC study investigated lymph nodes by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients with locally advanced non-small cell lung cancer (NSCLC). touchRESPIRATORY were delighted to speak with Dr. Daniel Steinfort (Royal Melbourne Hospital, Melbourne, Australia) to learn more around the aims, design and findings from the study and the importance of these findings […]

touchRESPIRATORY caught up with Dr. Paulo Rodrigues Santos (University of Coimbra, Coimbra, Portugal) to discuss the challenges associated with the use of anti-PD-1 therapy in phase IIIB/IV non-small cell lung cancer, the cellular and plasmatic immunosuppressive factors that affect the outcome of anti-PD-1 therapy and the data supporting the strategies used to overcome these immunosuppressive […]